|

|
TRANSURETHRAL
NEEDLE ABLATION (TUNA) OF CHRONIC NONBACTERIAL PROSTATITIS
|
|
| |
|
|
|
|
|
|
|
|
| |
|

|
Authors:
|

|
Jeong Gu Lee, Phil Bum
Jung, Jae Hoon Whang
|
|
| |
|
|
|
|
|
|
|
|
| |
|
|

|
Institution:
|

|
Department of Urology,
Korea University College of Medicine, Seoul, Korea
|
|
| |
|
|
|
|
|
|
|
|
| |
|
|
|
| |
|
|
|
|
|
|
|
|
| |
|
|
|
|
| |
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
| |
|
|
|
|
|
|
|
|
Aims of Study
We investigated the efficacy of transurethral needle ablation(TUNA) of prostate
for the treatment of chronic nonbacterial prostatitis (Category IIIA according
to the classifications of NIH1) not responsive to conservative managements.
Methods
We performed TUNA in 43 nonbacterial prostatitis patients in whom no clinical
management was useful to relieve the symptoms and signs of prostatitis. All
patients had excessive white blood cells (>10wbc) per high power field in expressed
prostatic fluid with no bacterial growth on urine and prostatic fluid cultures.
Preoperatively all patients were evaluated using symptom score, patient satisfaction
(quality of life) and prostatic fluid examination. These parameters were rechecked
at 1 and 3 months after TUNA in all patients. Of the total, 10 patients underwent
pre- and post-operative(at post op 3 mths.) semenalysis
Results
The symptom (from 11.02±2.90 to 5.00±2.61) and satisfaction(from 4.84±0.57 to
1.26±1.18) scores were improved significantly (p<0.05) at 3 months after the
TUNA. Of the 37 patients with >100 leukocyte count/hpf before TUNA, 26 patients
(70.3%) became normal at EPS within the 3 months after TUNA. Also, of the 42
patients with preoperative abnormal leukocyte counts, 30 patients (71.4%) had
normal EPS within the 3 months after TUNA. Of the 10 patients who underwent
semen analysis, changes of the semen quality was seen in no patient after the
TUNA.
Conclusions
TUNA appears to be an effective treatment for some patients with chronic nonbacterial
prostatitis unresponsive to conservative therapies. References 1. Chronic prostattis
Workshop; Summary of Statement. Bethesda, MD, National Institute of Health,
December 7-8, 1995.